Shares of Torrent Pharmaceuticals jumped nearly 5% during Friday’s session after global brokerage firm JPMorgan upgraded the stock to ‘Overweight’ and raised its target price to ₹3,800 from ₹3,650 earlier. The new target implies an upside potential of 18% from Thursday’s closing price.
JPMorgan cited strong growth momentum in India as a key driver for the upgrade, adding that the trend is expected to continue. The brokerage also highlighted improved visibility in Torrent Pharma’s Brazil business, supported by robust underlying performance and a favorable base effect following currency headwinds.
JPMorgan further noted Torrent’s positioning to benefit from the emerging GLP-1 opportunity in India, leveraging its leadership in cardiometabolic care. According to the brokerage, this could add 100–200 basis points to Torrent’s annual growth rate over time.
The firm also mentioned that Torrent’s Brazil business could see GLP-1 benefits in the future, though the impact may be delayed, with generic launches expected around mid-2026.
Torrent’s strong cash flow generation and its target to become debt-free by FY27 were also highlighted as positives. The stock is currently trading at 25x and 22x estimated earnings for FY26 and FY27, respectively.
Out of the 33 analysts covering Torrent Pharmaceuticals, 21 have a ‘Buy’ rating, seven rate it ‘Hold,’ and five recommend ‘Sell.’
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
